Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dolaut is a brand name for diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic, anti-inflammatory, and antipyretic properties. It functions as a small molecule inhibitor of the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby blocking the synthesis of prostaglandins, which are key mediators of pain and inflammation. Dolaut is available in several formulations, most notably a 4% topical gel spray, as well as tablets and ophthalmic solutions. It is primarily indicated for the treatment of acute and chronic painful and inflammatory conditions, including osteoarthritis, rheumatoid arthritis, migraine, and musculoskeletal injuries affecting joints, tendons, and ligaments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dolaut.